There are lots of Assay Development Events to choose from…. Why Should You Attend IIR’s? - New Regulatory Hot Topics not addressed anywhere else, including new white papers & regulatory clarification on potency assessment criteria, Risk Based FC Evaluation, Use of DoE and ISR for bioanalytical development and more...
- The largest most senior biopharmaceutical faculty with the most global perspectives represented
- The original community for cell based assays and bioanalytical scientists where the niche scientists can network and learn from leaders how to improve assay reliability
- More interactive learning formats that facilitate learning and the sharing of best practices than any other event
- What you need to know now to develop robust and reliable assays in just three days
- Two events in one with specific tracks on BioAnalytical Method Development & Cell Based Assays
Attend the 2010 Keynote PresentationsRegulatory Perspectives on Characterization and CMC Challenges with Antibody-Drug Conjugates Jun Park,PhD, Division of Monoclonal Antibodies, CDER/FDA NEW WHITE PAPER: Risk Based Strategies for How to Approach FC Function Evaluation An Song, PhD, Senior Scientist, Associate Director, GENENTECH 2009 Featured PresentationsCompare and Contrast Validation White Paper Screening Cut Point Calculations Martin Kane, Associate Director, Process Statistics A Neuronal Cell-based Assay for Highly Sensitive Detection of Pharmaceutical Preparations of BoNT/A and Patient Neutralizing Serum Antibodies Eric A. Johnson, Professor, Department of Bacteriology, Food Research Institute, University of Wisconsin, Madison | | Join the Conversation | | | Blog Feed | |
|